CA125联合HE4对Ⅱ型上皮性卵巢癌诊断及预后预测的研究  

Diagnosis and prognosis prediction of epithelial ovarian cancerⅡbased on CA125 combined with HE4

作　　者：赵娟[1] 魏星 杨婷[1] 赵敏伊 杨筱凤[1] Zhao Juan;Wei Xing;Yang Ting;Zhao Minyi;Yang Xiaofeng(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Xi’an Jiaotong University;Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Xi’an Jiaotong University)

机构地区：[1]西安交通大学第一附属医院妇产科,西安710061 [2]西安交通大学第二附属医院妇产科,西安710004

出　　处：《重庆医科大学学报》2020年第5期650-655,共6页Journal of Chongqing Medical University

基　　金：陕西省重点研发计划一般资助项目(编号:2017SF-016)。

摘　　要：目的:联合分析CA125及HE4的水平,评估其对Ⅱ型上皮性卵巢癌患者的术前诊断能力及与无进展间隔时间的相关性。方法:选取2012年4月至2014年10月共101例上皮性卵巢癌患者及同期卵巢上皮性良性肿瘤患者100例,进行CA125及HE4的检测及ROMA的计算,分析其与诊断及患者预后之间的关系。结果:良性肿瘤组与早期、晚期卵巢癌组在治疗前CA125及HE4的水平差异均有统计学意义(P=0.000),ROMA值在诊断卵巢癌中,敏感度、特异度、阴性预测值均为最高,误诊率及漏诊率最低,正确诊断指数最高;CA125、HE4及ROMA对Ⅱ型卵巢癌的诊断效率更高,尤其是ROMA值。治疗前CA125大于1 200 U/mL及HE4大于670 pmol/L的患者,再次出现复发的时间较短,疾病的无进展间隔缩短,差异具有统计学意义(CA125:χ2=20.926,P=0.000;HE4:χ2=11.235,P=0.001)。结论:CA125联合HE4检测对Ⅱ型上皮性卵巢癌的联合诊断能力较高。其术前水平与卵巢癌患者的无进展间隔负相关,可以辅助进行预后评估,值得在临床工作中推广和应用。Objective:Through combined analysis of CA125 and HE4 levels to assess its diagnosis and prognosis prediction value and association with progression-free interval in patients with epithelial ovarian cancerⅡ.Methods:One hundred and one patients with epithelial ovarian cancer and 100 patients with ovarian epithelial benign tumors from April 2012 to October 2014 were taken as the subjects.The detection of CA125 and HE4 and the calculation of ROMA were performed to analyze the relationship between diagnosis and prognosis.Results:The levels of CA125 and HE4 in the benign tumors group and early and advanced ovarian cancer were statis-tically different from each other before treatment(P=0.000).The sensitivity,specificity,and negative predictive value were the highest in the diagnosis of ovarian cancer,the misdiagnosis rate and the missed diagnosis rate were the lowest,and the correct diagnosis index was the highest;CA125,HE4 and ROMA had a higher diagnostic efficiency for epithelial ovarian cancerⅡ,especially ROMA values.Patients with CA125>1200 U/mL and HE4>670 Pmol/L before treatment had a short recurrence time,and a shorter progression-free interval.There was statistic difference(CA125:χ2=20.926,P=0.000;HE4:χ2=11.235,P=0.001).Conclusion:The combined diagnosis of CA125 combined with HE4 is superior in the diagnosis of epithelial ovarian cancerⅡ.Its preoperative level is negatively correlated with the progression-free interval of ovarian cancer patients,and it can assist the evaluation of prognosis.It is worthy of promotion and application in clinical work.

关 键 词：CA125 HE4 Ⅱ型上皮性卵巢癌 无进展间隔 

分 类 号：R711.75[医药卫生—妇产科学]